M Dougados

Summary

Country: France

Publications

  1. ncbi Validation of a short form of the Western Ontario and McMaster Universities Osteoarthritis Index function subscale in hip and knee osteoarthritis
    Gabriel Baron
    AP HP, Hopital Bichat, Département d Eidémiologie, Biostatistique et Recherche Clinique, INSERM, U738, Paris, France
    Arthritis Rheum 57:633-8. 2007
  2. ncbi Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders
    Florence Tubach
    Département d Epidémiologie, Biostatistique et Recherche Clinique, Hopital Bichat, Paris, France
    J Rheumatol 34:1188-93. 2007
  3. ncbi Evaluation of the patient acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: data from a randomized controlled trial
    Maxime Dougados
    Hôpital Cochin and University of Paris, Paris, France
    Arthritis Rheum 59:553-60. 2008
  4. ncbi A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial
    Maxime Dougados
    Paris Descartes University, and APHP, Rheumatology B Department, Cochin Hospital, Paris, France
    Ann Rheum Dis 69:1430-5. 2010
  5. ncbi Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases
    Guillaume Geri
    Paris Descartes University, Medicine Faculty, Assistance Publique Hopitaux de Paris, Rheumatology B Department, Cochin Hospital, Paris France
    BMC Infect Dis 11:304. 2011
  6. ncbi Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis
    Olivier Meyer
    Rheumatology Unit, Assistance Publique Hopitaux de Paris, Bichat University Hospital, 75018 Paris, France
    Arthritis Res Ther 8:R40. 2006
  7. ncbi Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor ?-blockers: a case-control study
    Melanie Gilson
    Rheumatology B Department, Cochin Hospital, Paris 75014, France
    Arthritis Res Ther 12:R145. 2010
  8. ncbi The influence of the definition of patient global assessment in assessment of disease activity according to the Disease Activity Score (DAS28) in rheumatoid arthritis
    Maxime Dougados
    Department of Rheumatology B, Cochin Hospital, Paris Pfizer SAS France, Paris France
    J Rheumatol 38:2326-8. 2011
  9. ncbi Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE)
    M Dougados
    Paris Descartes University, UPRES EA 4058, and APHP, Rheumatology B Department, Cochin Hospital, Paris, France
    Ann Rheum Dis 70:799-804. 2011
  10. ncbi Nonsteroidal antiinflammatory drug intake according to the Assessment of SpondyloArthritis International Society Score in clinical trials evaluating tumor necrosis factor blockers: example of etanercept in advanced ankylosing spondylitis
    Maxime Dougados
    Paris Descartes University, UPRES EA 4058, AP HP, Cochin Hospital, Paris 14, France
    Arthritis Care Res (Hoboken) 64:290-4. 2012

Collaborators

Detail Information

Publications169 found, 100 shown here

  1. ncbi Validation of a short form of the Western Ontario and McMaster Universities Osteoarthritis Index function subscale in hip and knee osteoarthritis
    Gabriel Baron
    AP HP, Hopital Bichat, Département d Eidémiologie, Biostatistique et Recherche Clinique, INSERM, U738, Paris, France
    Arthritis Rheum 57:633-8. 2007
    ..The goal of the present study was to validate this short form...
  2. ncbi Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders
    Florence Tubach
    Département d Epidémiologie, Biostatistique et Recherche Clinique, Hopital Bichat, Paris, France
    J Rheumatol 34:1188-93. 2007
    ..The purpose of this SIG at OMERACT 8 was to inform participants of the MCII and PASS concepts and to agree on MCII and PASS values for pain, patient global assessment, and functional impairment...
  3. ncbi Evaluation of the patient acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: data from a randomized controlled trial
    Maxime Dougados
    Hôpital Cochin and University of Paris, Paris, France
    Arthritis Rheum 59:553-60. 2008
    ..To evaluate the feasibility/acceptability, reliability, external validity, and discriminant capacity of the Patient Acceptable Symptom State (PASS) concept in patients with active ankylosing spondylitis (AS)...
  4. ncbi A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial
    Maxime Dougados
    Paris Descartes University, and APHP, Rheumatology B Department, Cochin Hospital, Paris, France
    Ann Rheum Dis 69:1430-5. 2010
    ..The objective of this study was to investigate the efficacy of etanercept in refractory heel enthesitis related to SpA...
  5. ncbi Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases
    Guillaume Geri
    Paris Descartes University, Medicine Faculty, Assistance Publique Hopitaux de Paris, Rheumatology B Department, Cochin Hospital, Paris France
    BMC Infect Dis 11:304. 2011
    ..Data are lacking on the risk of lower respiratory tract infections in patients treated with biologic agents...
  6. ncbi Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis
    Olivier Meyer
    Rheumatology Unit, Assistance Publique Hopitaux de Paris, Bichat University Hospital, 75018 Paris, France
    Arthritis Res Ther 8:R40. 2006
    ..In conclusion, serially determined anti-CCP2 antibodies during the first three years of follow-up performs better than baseline determination for predicting radiographic progression in patients with early RA...
  7. ncbi Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor ?-blockers: a case-control study
    Melanie Gilson
    Rheumatology B Department, Cochin Hospital, Paris 75014, France
    Arthritis Res Ther 12:R145. 2010
    ....
  8. ncbi The influence of the definition of patient global assessment in assessment of disease activity according to the Disease Activity Score (DAS28) in rheumatoid arthritis
    Maxime Dougados
    Department of Rheumatology B, Cochin Hospital, Paris Pfizer SAS France, Paris France
    J Rheumatol 38:2326-8. 2011
    ..We studied the influence of the use of 3 different techniques of PGA on the assessment of disease activity...
  9. ncbi Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE)
    M Dougados
    Paris Descartes University, UPRES EA 4058, and APHP, Rheumatology B Department, Cochin Hospital, Paris, France
    Ann Rheum Dis 70:799-804. 2011
    ..This placebo-controlled study evaluated the effect of etanercept (ETN) in patients with advanced AS...
  10. ncbi Nonsteroidal antiinflammatory drug intake according to the Assessment of SpondyloArthritis International Society Score in clinical trials evaluating tumor necrosis factor blockers: example of etanercept in advanced ankylosing spondylitis
    Maxime Dougados
    Paris Descartes University, UPRES EA 4058, AP HP, Cochin Hospital, Paris 14, France
    Arthritis Care Res (Hoboken) 64:290-4. 2012
    ..To evaluate the interest of the Assessment of SpondyloArthritis international Society (ASAS) nonsteroidal antiinflammatory drug (NSAID) score as a quality indicator and a potential outcome measure in clinical studies...
  11. ncbi OARSI/OMERACT criteria of being considered a candidate for total joint replacement in knee/hip osteoarthritis as an endpoint in clinical trials evaluating potential disease modifying osteoarthritic drugs
    Maxime Dougados
    Paris Descartes University, Medicine Faculty, UPRES EA 4058, AP HP, Cochin Hospital, Rheumatology B Department, Paris, France
    J Rheumatol 36:2097-9. 2009
    ..We propose a composite index including structural and symptomatic variables of osteoarthritis (OA) as criteria for being considered a candidate for total joint replacement as an endpoint in clinical trials evaluating potential DMOAD...
  12. ncbi Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis
    Maxime Dougados
    Department of Rheumatology, Hopital Cochin, 27 rue du Faubourg Saint Jacques, 75014 Paris, France
    Arthritis Res Ther 9:R11. 2007
    ..Trial registration numbers: NCT00366938 and NCT00367315...
  13. ncbi [The process of generating EULAR recommendations]
    M Dougados
    Paris Descartes University, Medicine Faculty, UPRES EA 4058 APHP, Cochin Hospital, Rheumatology B Department, Paris, Frankreich
    Z Rheumatol 69:305-9. 2010
    ..g., experts). Such a process has improved the knowledge of both the fellows and the experts in the field of clinical epidemiology...
  14. ncbi Why and how to use NSAIDs in osteoarthritis
    Maxime Dougados
    Medicine Faculty, Rene Descartes University, and Rheumatology B Department, AP HP Cochin Hospital, Paris, France
    J Cardiovasc Pharmacol 47:S49-54. 2006
    ....
  15. ncbi EULAR efforts to define quality of care
    M Dougados
    Paris Descartes University, Medicine Faculty, Cochin Hospital, Paris, France
    Clin Exp Rheumatol 25:14-7. 2007
    ..Moreover, EULAR is promoting educational programs and is lobbying at the European Community level in order to improve the recognition of musculo-skeletal disorders...
  16. ncbi The DESIR cohort: A 10-year follow-up of early inflammatory back pain in France: Study design and baseline characteristics of the 708 recruited patients
    Maxime Dougados
    Paris Descartes University, Medicine Faculty, UPRES EA 4058, AP HP, Cochin Hospital, Rheumatology B Department, Paris 14, France
    Joint Bone Spine 78:598-603. 2011
    ....
  17. ncbi EULAR report on the use of ultrasonography in painful knee osteoarthritis. Part 1: prevalence of inflammation in osteoarthritis
    P Conaghan
    Rheumatology Department, Cochin Hospital, Paris, France
    Ann Rheum Dis 64:1703-9. 2005
    ..77 for joint effusion). CONCLUSION: US can detect synovial inflammation and effusion in painful knee OA, which correlate significantly with knee synovitis, effusion, and clinical parameters suggestive of an inflammatory "flare"...
  18. ncbi Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative
    L Gossec
    Paris Descartes University, Medicine Facility, APHP, Rheumatology B Department, Cochin Hospital, Paris, France
    Ann Rheum Dis 70:935-42. 2011
    ..The objectives were to finalise the RAID and examine its psychometric properties...
  19. ncbi Laterally elevated wedged insoles in the treatment of medial knee osteoarthritis: a prospective randomized controlled study
    J F Maillefert
    Cochin Hospital, Rheumatology B, , Paris, France
    Osteoarthritis Cartilage 9:738-45. 2001
    ..However, the decrease in NSAIDs consumption together with better compliance in the treated group are in favor of a beneficial effect of laterally-wedged insoles in medial femoro-tibial OA...
  20. ncbi Clinical and ultrasonographic predictors of joint replacement for knee osteoarthritis: results from a large, 3-year, prospective EULAR study
    P G Conaghan
    Paris Descartes University, Medicine Faculty, UPRES EA 4058 and APHP, Rheumatology B Department, Cochin Hospital, 27 rue du Faubourg St Jacques, Paris, France
    Ann Rheum Dis 69:644-7. 2010
    ..To determine clinical and ultrasonographic predictors of joint replacement surgery across Europe in primary osteoarthritis (OA) of the knee...
  21. ncbi Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study
    S Guignard
    Rene Descartes University, Medicine Faculty, APHP, Cochin Hospital, Rheumatology B Department, Paris, France
    Ann Rheum Dis 65:1631-4. 2006
    ..To evaluate the efficacy of anti-tumour necrosis factor (TNF) treatments (given for rheumatological manifestations) in reducing uveitis flares in patients with spondylarthropathy in daily practice...
  22. ncbi Evaluation of disease activity assessments in patients with rheumatoid arthritis and an inadequate response to anti-TNF therapy: analyses of abatacept clinical trial data
    M Dougados
    Rene Descartes University, Medicine Faculty, Hospital Cochin, Rheumatology B Department, Paris, France
    Clin Exp Rheumatol 28:258-60. 2010
    ....
  23. ncbi [Spondyloarthropathy: MR imaging features]
    A Feydy
    Service de Radiologie B, Universite Paris Descartes, Hopital Cochin, AP HP, Paris, France
    J Radiol 91:1057-67. 2010
    ..MRI frequently allows early diagnosis of inflammatory lesions in patients with normal plain films. In addition, MRI is useful for the detection and quantification of inflammatory and structural lesions, and to assess disease activity...
  24. ncbi Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up
    L Gossec
    Rheumatologie B, Hopital Cochin, 27 rue du Fbg St Jacques, 75014 Paris, France
    Rheumatology (Oxford) 45:859-62. 2006
    ..To evaluate the continuation and safety of treatment with infliximab in ankylosing spondylitis (AS) over a 2-yr period...
  25. ncbi Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers
    A Ruyssen Witrand
    Paris Rene Descartes University, Medicine Faculty, AP HP, Cochin Hospital, Rheumatology B Department, Paris, France
    Clin Exp Rheumatol 25:430-6. 2007
    ..The aim of this study was to assess the complication rate after surgery in such patients, to assess the effect of interrupting TNF blocker therapy, and to identify other potential predictors of complications...
  26. ncbi Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip
    M Dougados
    Université René Descartes and Hôpital Cochin, Service de Rhumatologie B, Paris, France
    Arthritis Rheum 44:2539-47. 2001
    ..To evaluate the ability of diacerein, an interleukin-1beta inhibitor, to slow the progressive decrease in joint space width observed in patients with hip osteoarthritis (OA)...
  27. ncbi Comparative evaluation of three semi-quantitative radiographic grading techniques for knee osteoarthritis in terms of validity and reproducibility in 1759 X-rays: report of the OARSI-OMERACT task force
    L Gossec
    Paris Descartes University, Medicine Faculty, UPRES EA 4058, Paris, France
    Osteoarthritis Cartilage 16:742-8. 2008
    ..The objective of this work was to compare the measurement properties of three categorical X-ray scoring methods of knee osteoarthritis (OA), both on semiflexed and extended views...
  28. ncbi Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data
    M Dougados
    Rene Descartes University, Medicine Faculty, UPRES EA 4058, APHP, Cochin Hospital, Rheumatology B Department, Paris, France
    Ann Rheum Dis 68:484-9. 2009
    ....
  29. ncbi Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study
    L Gossec
    , Cochin Hospital, Department of Rheumatology B, Paris, France
    Ann Rheum Dis 63:675-80. 2004
    ..CONCLUSIONS: Baseline prognostic factors for remission in early rheumatoid arthritis were mainly clinical markers of disease activity and radiological scores...
  30. ncbi Relevant change in radiological progression in patients with hip osteoarthritis. II. Determination using an expert opinion approach
    J F Maillefert
    , Cochin Hospital, Institut de Rhumatologie, Paris, France
    Rheumatology (Oxford) 41:148-52. 2002
    ..7 respectively. CONCLUSION: This study suggests that a change of at least 0.4 mm in the radiological JSW could be considered clinically relevant. Other studies using other sets of patients and other methods are needed for validation...
  31. ncbi Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis -- results of a 1 year longitudinal arthroscopic study in 422 patients
    X Ayral
    Service de Rhumatologie B, Hopital Cochin, AP HP, Universite Rene Descartes, Paris, France
    Osteoarthritis Cartilage 13:361-7. 2005
    ..To evaluate the prevalence of synovitis in painful medial tibiofemoral knee osteoarthritis (OA) and to evaluate correlation between synovitis and the structural severity and progression of tibiofemoral cartilage damage...
  32. ncbi [MR Imaging of the spine and sacroiliac joints in ankylosing spondylitis]
    A Feydy
    Universite Paris Descartes, Hopital Cochin, AP HP, Paris, France
    J Radiol 91:140-50. 2010
    ..Moreover, MRI is useful for the detection and quantification of inflammatory and structural lesions, and to assess disease activity...
  33. ncbi Clinical relevance of C-reactive protein in axial involvement of ankylosing spondylitis
    M Dougados
    Université René Descartes and Hôpital Cochin, Paris, France
    J Rheumatol 26:971-4. 1999
    ..This outcome measure does not seem to be of great interest in the short term evaluation of fast acting drugs. However, the longterm clinical significance of such an increase in CRP remains to be investigated...
  34. ncbi Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort
    M Soubrier
    Department of Rheumatology, Hopital G Montpied, 63003 Clermont Ferrand, France
    Ann Rheum Dis 70:611-5. 2011
    ....
  35. ncbi The role of pain and functional impairment in the decision to recommend total joint replacement in hip and knee osteoarthritis: an international cross-sectional study of 1909 patients. Report of the OARSI-OMERACT Task Force on total joint replacement
    L Gossec
    Paris Descartes University, Medicine Faculty, APHP, Rheumatology B Department, Cochin Hospital, Paris, France
    Osteoarthritis Cartilage 19:147-54. 2011
    ..To assess the pain and functional disability levels corresponding to an indication for total joint replacement (TJR) in hip and knee osteoarthritis (OA)...
  36. ncbi Predictive factors of total hip replacement due to primary osteoarthritis: a prospective 2 year study of 505 patients
    L Gossec
    Service de Rhumatologie B, Hopital Cochin, 27, rue du Faubourg Saint Jacques, 75014 Paris, France
    Ann Rheum Dis 64:1028-32. 2005
    ..To determine the 2 year total hip replacement (THR) rate and to identify factors predictive of THR due to primary osteoarthritis (OA)...
  37. ncbi Management of osteoarthritis (OA) with an unsupervised home based exercise programme and/or patient administered assessment tools. A cluster randomised controlled trial with a 2x2 factorial design
    P Ravaud
    , , , , Paris et INSERM U444, Paris, France
    Ann Rheum Dis 63:703-8. 2004
    ....
  38. ncbi Sex differences in hip osteoarthritis: results of a longitudinal study in 508 patients
    J F Maillefert
    Institut de Rhumatologie, , Cochin Hospital, Paris, France
    Ann Rheum Dis 62:931-4. 2003
    ..CONCLUSION: Hip OA in women is more frequently part of a polyarticular OA, and displays greater symptomatic and structural severity...
  39. ncbi Reporting of patient-reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review
    U Kalyoncu
    Paris Descartes University, Medicine Faculty, Paris, France
    Ann Rheum Dis 68:183-90. 2009
    ..The objective of this study was to assess the frequency of use of different PROs in recently published RA articles and to compare the tools used through a systemic literature review...
  40. ncbi Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients
    C Salliot
    Rene Descartes University, Medicine Faculty, AP HP, Cochin Hospital, Rheumatology B Department, Paris, France
    Rheumatology (Oxford) 46:327-34. 2007
    ..To evaluate the rate of infections in rheumatic patients treated with tumour necrosis factor (TNF)-alpha blockers in daily practice and to determine potential risk factors of infections...
  41. ncbi Comparison of the clinical characteristics of vasculitis occurring during anti-tumor necrosis factor treatment or not in rheumatoid arthritis patients. A systematic review of 2707 patients, 18 vasculitis
    S Guignard
    Universite Rene Descartes, Faculte de Medecine, AP HP, Hopital Cochin, Service de Rhumatologie B, Paris, France
    Clin Exp Rheumatol 26:S23-9. 2008
    ..Comparison of vasculitis occurring in rheumatoid arthritis (RA) patients undergoing anti-tumor necrosis factor (TNF) treatment and those not...
  42. ncbi Cost effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: economic evaluation within a randomised controlled trial
    B Fautrel
    APHP, Groupe Hospitalier Pitie Salpetriere, Service of Rhumatologie, Paris, France
    Ann Rheum Dis 69:424-7. 2010
    ..To determine the incremental cost-effectiveness ratios (ICERs) of two therapeutic regimens of infliximab for ankylosing spondylitis (AS)...
  43. ncbi Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor {alpha} treatment
    K Briot
    Hopital Cochin, Departement de Rhumatologie, 27 rue du Faubourg St Jacques, 75014 Paris, France
    Ann Rheum Dis 64:1137-40. 2005
    ..To determine the changes in body weight, body composition, and bone turnover in patients with spondyloarthropathy (SpA) treated with anti-tumour necrosis factor alpha (TNFalpha)...
  44. ncbi The role of anti-inflammatory drugs in the treatment of osteoarthritis: a European viewpoint
    M Dougados
    Rene Descartes University, Cochin Hospital, Rheumatology B Department, 27 rue de Faubourg Saint Jacques, 75014 Paris, France
    Clin Exp Rheumatol 19:S9-14. 2001
    ..However, two questions remain: the choice of NSAIDs versus analysis as first line therapy for symptomatic treatment in OA, and the long-term structural effect of such therapy...
  45. ncbi Recurrence of spondylarthropathy among first-degree relatives of patients: a systematic cross-sectional study
    E Dernis
    Rheumatology Division, Cochin Hospital, Assistance Publique des Hopitaux de Paris, Paris, France
    Ann Rheum Dis 68:502-7. 2009
    ..To examine the recurrence of manifestations belonging to the spectrum of spondylarthropathy (SpA) in first-degree relatives of patients with SpA, and to estimate the recurrence risk ratio...
  46. ncbi Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials
    C Salliot
    Rene Descartes University, Medicine Faculty, AP HP, Cochin Hospital, Rheumatology B Department, Paris, France
    Ann Rheum Dis 68:25-32. 2009
    ..Recently, new biological agents have become available. Their safety is an important issue...
  47. ncbi EULAR report on the use of ultrasonography in painful knee osteoarthritis. Part 2: exploring decision rules for clinical utility
    P Conaghan
    Rheumatology Department, Cochin Hospital, 27, rue du Faubourg St Jacques, 75014 Paris, France
    Ann Rheum Dis 64:1710-4. 2005
    ..Thus sensitive imaging techniques such as US remain the most useful tool for demonstrating synovial inflammation of the knee at the individual level...
  48. ncbi Leflunomide in rheumatoid arthritis in daily practice: treatment discontinuation rates in comparison with other DMARDs
    I Bettembourg-Brault
    Rheumatology B Department, Cochin Hospital, AP-HP, Rene Descartes University, Paris, France
    Clin Exp Rheumatol 24:168-71. 2006
    ..CONCLUSION: This study conducted in conditions of daily practice when leflunomide was first available suggests a higher discontinuation rate of leflunomide because of adverse events when compared to other DMARDs...
  49. ncbi Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study
    J F Maillefert
    Department of Rheumatology, Dijon University Hospital, France
    Osteoporos Int 12:605-9. 2001
    ..1% +/- 5.7 and -1.2% +/- 3.9 in patients with and without persistent inflammation; respectively; p = 0.007). These results suggest that persistent inflammation might be an etiologic factor of bone loss in AS...
  50. ncbi Comparative evaluation of three semi-quantitative radiographic grading techniques for hip osteoarthritis in terms of validity and reproducibility in 1404 radiographs: report of the OARSI-OMERACT Task Force
    L Gossec
    Paris Descartes University, Medicine Faculty, UPRES EA 4058, APHP, Rheumatology B Department, Cochin Hospital, Paris, France
    Osteoarthritis Cartilage 17:182-7. 2009
    ..The objective of this work was to compare the measurement properties of three categorical X-ray scoring methods for hip osteoarthritis (OA)...
  51. ncbi Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug
    M Dougados
    , Cochin Hospital, Paris, France
    Arthritis Rheum 44:180-5. 2001
    ..CONCLUSION: The results of this study confirm the clinically relevant antiinflammatory effect of celecoxib at a 200-mg daily dosage, with significant improvement of both pain and function in patients with AS...
  52. ncbi Individualising the Western Ontario and McMaster Universities osteoarthritis index (WOMAC) function subscale: incorporating patient priorities for improvement to measure functional impairment in hip or knee osteoarthritis
    R Seror
    AP HP, Hopital Bichat, Département d Epidémiologie, Biostatistique et Recherche Clinique, INSERM, U738, Paris, France
    Ann Rheum Dis 67:494-9. 2008
    ....
  53. ncbi Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis
    L Gossec
    Hopital Cochin, Rhumatologie B, Paris, France
    Ann Rheum Dis 64:1563-7. 2005
    ..The combined efficacy of selective and non-selective cyclo-oxygenase-2 (COX-2) inhibition on the axial manifestations of ankylosing spondylitis (AS) in the presence or absence of chronic peripheral arthritis was evaluated...
  54. ncbi [US evaluation of the hands and feet in rheumatoid arthritis]
    H Guerini
    Service de Radiologie B, Hopital Cochin, 75014 Paris, France
    J Radiol 91:99-110. 2010
    ..In this article, we will describe this protocol used daily in our institution for early diagnosis and therapeutic management of this disease...
  55. ncbi Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha
    F Allali
    Rheumatology Department, , Cochin Hospital, Paris, France
    Ann Rheum Dis 62:347-9. 2003
    ..35, p=0.06). CONCLUSION: These data suggest that a benefit of anti-tumour necrosis factor alpha therapy on BMD in patients with SpA may be through an uncoupling effect on bone cells...
  56. ncbi Influence of flare design on symptomatic efficacy of non-steroidal anti-inflammatory drugs in osteoarthritis: a meta-analysis of randomized placebo-controlled trials
    S Trijau
    Paris Descartes University, Medicine Faculty, UPRES EA 4058, France
    Osteoarthritis Cartilage 18:1012-8. 2010
    ..e., including only patients with an increase in their pain after stopping their usual treatment (NSAIDs or analgesic)...
  57. ncbi Assessment of progression in knee osteoarthritis: results of a 1 year study comparing arthroscopy and MRI
    E Pessis
    Department of Radiology B, Hopital Cochin 27, AP HP, Universite Paris V, rue du Faubourg Saint Jacques, 75679 Paris Cedex 14, France
    Osteoarthritis Cartilage 11:361-9. 2003
    ....
  58. ncbi Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients
    Muriel Duclos
    Rene Descartes University, Faculty of Medicine, Paris, France
    J Rheumatol 33:2433-8. 2006
    ..Moreover, results suggest greater benefit in SpA. The role of concomitant DMARD remains to be confirmed...
  59. ncbi European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies
    L Gossec
    Correspondence to Dr Laure Gossec, Service de Rhumatologie B, Hopital Cochin, 27, rue du Faubourg Saint Jacques, 75014 Paris, France
    Ann Rheum Dis 71:4-12. 2012
    ..The authors present European League Against Rheumatism (EULAR) recommendations for the treatment of PsA with systemic or local (non-topical) symptomatic and disease-modifying antirheumatic drugs (DMARD)...
  60. ncbi Multi-language translation and cross-cultural adaptation of the OARSI/OMERACT measure of intermittent and constant osteoarthritis pain (ICOAP)
    J F Maillefert
    Department of Rheumatology, Dijon University Hospital, Dijon F 21078, France
    Osteoarthritis Cartilage 17:1293-6. 2009
    ..To conduct a multi-language translation and cross-cultural adaptation of the Intermittent and Constant OsteoArthritis Pain (ICOAP) questionnaire for hip and knee osteoarthritis (OA)...
  61. ncbi Ultrasonic backscatter and transmission parameters at the os calcis in postmenopausal osteoporosis
    C Roux
    , Hĵpital Cochin, , Paris, France
    J Bone Miner Res 16:1353-62. 2001
    ..However, BUB evaluation, which does not require two transducers and may be implemented in conventional reflection mode systems, warrants further studies...
  62. ncbi Psychometric properties of the OARSI/OMERACT osteoarthritis pain and functional impairment scales: ICOAP, KOOS-PS and HOOS-PS
    A Ruyssen-Witrand
    Rheumatology B Department, Cochin Hospital, Paris, France
    Clin Exp Rheumatol 29:231-7. 2011
    ..To evaluate the psychometric properties of the OARSI-OMERACT questionnaires in comparison to the existing validated scales...
  63. ncbi Glucocorticoid sparing effect of tumour necrosis factor alpha inhibitors in rheumatoid arthritis in real life practice
    R Seror
    Paris Descartes University, Cochin Hospital, France
    Clin Exp Rheumatol 27:807-13. 2009
    ..To determine, in real life practice, the impact of anti-tumour necrosis factor (TNF)-alpha on glucocorticoid (GC) use in rheumatoid arthritis (RA) patients...
  64. ncbi An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis
    T Pham
    Department of Rheumatology, Aix Marseille II University, Conception Hospital, 147 Bd Baille, 13005 Marseille, France
    Ann Rheum Dis 65:1620-5. 2006
    ....
  65. ncbi HLA DRB1*01 and DRB1*04 phenotyping does not predict the need for joint surgery in rheumatoid arthritis. A retrospective quantitative evaluation of 300 French patients
    L Gossec
    Service de Rhumatologie B, Universite Rene Descartes, Centre Hospitalier Universitaire Cochin, Paris, France
    Clin Exp Rheumatol 22:462-4. 2004
    ..To determine if the presence of HLA-DR disease-associated epitopes predicts the need for total joint arthroplasty or joint fusion in rheumatoid arthritis (RA)...
  66. ncbi OARSI-OMERACT definition of relevant radiological progression in hip/knee osteoarthritis
    P Ornetti
    Universite de Bourgogne, Medicine Faculty, Dijon University Hospital, Rheumatology Department, Dijon, France
    Osteoarthritis Cartilage 17:856-63. 2009
    ....
  67. ncbi DNA microarray allows molecular profiling of rheumatoid arthritis and identification of pathophysiological targets
    V Devauchelle
    Institut Cochin, Paris, France
    Genes Immun 5:597-608. 2004
    ..It is proposed that such an approach allows valuable diagnosis/prognostics tools in RA to be established and potential targets for combating the disease to be identified...
  68. ncbi Combination therapy in early rheumatoid arthritis
    L Gossec
    , Cochin Hospital, Paris, France
    Clin Exp Rheumatol 21:S174-8. 2003
    ..It appears likely that the place of combination therapy will increase in the coming decades, even in very early RA patients, where the ultimate goal is persistent remission...
  69. ncbi Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative
    L Gossec
    Paris Descartes University, Medicine Faculty, UPRES EA 4058, APHP, Rheumatology B Department, Cochin Hospital, Paris France
    Ann Rheum Dis 68:1680-5. 2009
    ..Current response criteria in rheumatoid arthritis (RA) usually assess only three patient-reported outcomes (PROs): pain, functional disability and patient global assessment. Other important PROs such as fatigue are not included...
  70. ncbi Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage
    O Meyer
    Service de Rhumatologie, CHU Bichat, AP HP, Paris, France
    Ann Rheum Dis 62:120-6. 2003
    ..To study the value of antibodies to citrullinated proteins/peptides for predicting joint outcomes in patients with recent onset rheumatoid arthritis (RA)...
  71. ncbi Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists
    L Gossec
    Paris Descartes University, Medicine Faculty, UPRES EA 4058 APHP, Rheumatology B Department, Cochin Hospital, Paris, France
    Ann Rheum Dis 67:782-8. 2008
    ..Ten ASAS/EULAR recommendations for the management of ankylosing spondylitis (AS) were published in 2006...
  72. ncbi Paracetamol in osteoarthritis of the knee
    C Miceli-Richard
    Cochin Hospital, AP-HP, , Paris, France
    Ann Rheum Dis 63:923-30. 2004
    ..The tolerability and safety of paracetamol, at the recommended maximum dose of 4 g/day, was confirmed over 6 weeks...
  73. ncbi Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial
    Martin Soubrier
    Department of Rheumatology, Hopital G Montpied, 63003 Clermont Ferrand, France
    Rheumatology (Oxford) 48:1429-34. 2009
    ..To compare this strategy with an initial combination of MTX and adalimumab (ADA) given for 3 months and then adjusted based on the disease activity status...
  74. ncbi Initiation of biological agents in patients with ankylosing spondylitis: results of a Delphi study by the ASAS Group
    T Pham
    , AP-HP, Rheumatology B Department, Cochin Hospital, Paris, France
    Ann Rheum Dis 62:812-6. 2003
    ..Further studies are required to assess their relevance and their consistency with clinical practice...
  75. ncbi Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review
    J Avouac
    , Medicine Faculty, and APHP Cochin Hospital, Rhumatologie B Department, Paris, France
    Ann Rheum Dis 65:845-51. 2006
    ..Moreover, anti-CCP antibodies appear to be highly predictive of the future development of RA in both healthy subjects and patients with undifferentiated arthritis...
  76. ncbi Intra-articular treatments in osteoarthritis: from the symptomatic to the structure modifying
    L Gossec
    René Discartes University, Cochin Hospital, Rheumatology B Department, Paris, France
    Ann Rheum Dis 63:478-82. 2004
    ..Hyaluronan has delayed onset of efficacy but its benefit for pain may be longer lasting. Lavage and debridement are probably not as efficacious as once thought in osteoarthritis...
  77. ncbi Self-reported prevalence of psoriasis and evaluation of the impact on the natural history of hip osteoarthritis: results of a 10 years follow-up study of 507 patients (ECHODIAH study)
    Umut Kalyoncu
    Paris Descartes University, Medicine Faculty, UPRES EA 4058, APHP, Rheumatology B Department, Cochin Hospital, Paris, France
    Joint Bone Spine 76:389-93. 2009
    ..The objective of the present study was to assess the frequency of self-reported psoriasis in a hip osteoarthritis (OA) cohort, and a secondary objective was to assess the course of hip OA with psoriasis...
  78. ncbi Feeling good rather than feeling better matters more to patients
    Florence Tubach
    Assistance Publique Hopitaux de Paris, Hopital Bichat, INSERM U738, Universite Paris 7 Denis Diderot, Paris, France
    Arthritis Rheum 55:526-30. 2006
    ....
  79. ncbi OMERACT/OARSI initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis
    Laure Gossec
    Medicine Faculty, Paris 5 René Descartes University AP HP, Cochin Hospital, Department of Rheumatology B, Paris, France
    J Rheumatol 34:1432-5. 2007
    ..quot;..
  80. ncbi Impact of ultrasound imaging on local corticosteroid injections of symptomatic ankle, hind-, and mid-foot in chronic inflammatory diseases
    Xavier Ayral
    Cochin Hospital, , Paris, France
    Arthritis Rheum 53:284-92. 2005
    ..0170). CONCLUSION: US frequently led the physician to change his diagnosis of inflammatory lesions in painful foot, and consequently his planning of CS injections. Moreover, US could improve the response to local treatment...
  81. ncbi When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?
    M Dougados
    Hopital Cochin, Rene Descartes University, 27, rue du Faubourg Saint Jacques, 75679 Paris Cedex 14, France
    Ann Rheum Dis 64:44-51. 2005
    ..To evaluate the efficacy and safety of adding sulfasalazine to leflunomide treatment compared with switching to sulfasalazine alone in patients with RA with an inadequate response to leflunomide monotherapy...
  82. ncbi Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study
    M Breban
    Institut de Rhumatologie, , , Paris, France
    Rheumatology (Oxford) 41:1280-5. 2002
    ..Relapse usually occurred after discontinuation of the drug, but almost one-third of completers were still free of relapse 4 months after the last infusion...
  83. ncbi Treatment of spondyloarthropathies. Recent advances and prospects in 2001
    M Dougados
    Universite Rene Descartes, Department of Rheumatology B, Hopital Cochin, Paris, France
    Joint Bone Spine 68:557-63. 2001
    ..Importantly, maintenance treatment seems effective not only on peripheral joint manifestations but also on axial manifestations that fail to respond to NSAIDs. Thalidomide and TNF antagonists are promising maintenance agents...
  84. ncbi Arthroscopic evaluation of potential structure-modifying drug in osteoarthritis of the knee. A multicenter, randomized, double-blind comparison of tenidap sodium vs piroxicam
    X Ayral
    Service de Rhumatologie B, Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Rene Descartes, Paris, France
    Osteoarthritis Cartilage 11:198-207. 2003
    ..To test the hypothesis that tenidap has a structure-modifying effect in human knee osteoarthritis...
  85. ncbi Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data
    Maxime Dougados
    , , 27 rue du Faubourg Saint-Jacques, 75679 Paris Cedex 14, France
    J Rheumatol 30:2572-9. 2003
    ..CONCLUSION: This study demonstrates that leflunomide is well tolerated, with a safety profile similar to that seen previously in Phase III studies, and confirms the efficacy of leflunomide across a range of patient categories...
  86. ncbi Symptomatic slow-acting drugs for osteoarthritis: what are the facts?
    Maxime Dougados
    Rheumatology Department, Cochin Teaching Hospital, School of Medicine, Paris Descartes University, Assistance Publique Hopitaux de Paris, 27, rue du Faubourg Saint Jacques, 75014 Paris, France
    Joint Bone Spine 73:606-9. 2006
    ..In addition, the characteristics of the patients who are most likely to benefit from SySADOA need to be identified...
  87. ncbi Stability of the patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis
    Florence Tubach
    Assistance Publique Hopitaux de Paris, Bichat Hospital, University Paris VII, INSERM U738, Paris, France
    Arthritis Rheum 55:960-3. 2006
    ..Our goal was to determine the PASS in main outcome criteria when assessing patients with ankylosing spondylitis (AS) and to evaluate whether the PASS is stable over time...
  88. ncbi Frequency and tolerance of antituberculosis treatment according to national guidelines for prevention of risk of tuberculosis due to tumor necrosis factor blocker treatment
    Marie Gaëlle Bray
    Paris Descartes University, Medicine Faculty, UPRES EA 4058, 75651 Paris, France
    Joint Bone Spine 77:135-41. 2010
    ..However, its toxicity is unknown in this context and is a subject of debate...
  89. ncbi Reproducibility and sensitivity to change of various methods to measure joint space width in osteoarthritis of the hip: a double reading of three different radiographic views taken with a three-year interval
    Emmanuel Maheu
    Service de Rhumatologie, Hopital Saint Antoine, Paris, France
    Arthritis Res Ther 7:R1375-85. 2005
    ..6 or greater for assessing JSN over three years. Selecting a single reader was the most accurate method, with 0.3 mm precision. Using this cutoff, 50% of patients were classified as 'progressors'...
  90. ncbi The methods for handling missing data in clinical trials influence sample size requirements
    Guy-Robert Auleley
    , , , AP-HP, Paris, France
    J Clin Epidemiol 57:447-53. 2004
    ..CONCLUSIONS: These results can help investigators plan clinical trials to select the primary outcome and a priori specify the way missing data will be handled...
  91. ncbi Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis
    Bruno Fautrel
    Pierre and Marie Curie University Paris VI, UFR de Medecine, France
    Joint Bone Spine 74:627-37. 2007
    ..To update French Society for Rheumatology guidelines regarding the use of TNFalpha antagonists for treating patients with rheumatoid arthritis (RA)...
  92. ncbi Reporting of adherence to medication in recent randomized controlled trials of 6 chronic diseases: a systematic literature review
    Laure Gossec
    AP HP, Rheumatology B Department, Cochin Hospital, 27 rue du Faubourg St Jacques, Paris 5 University, Paris, France
    Am J Med Sci 334:248-54. 2007
    ....
  93. ncbi Hormonal replacement therapy may reduce the risk for RA in women with early arthritis who carry HLA-DRB1 *01 and/or *04 alleles by protecting against the production of anti-CCP: results from the ESPOIR cohort
    Carine Salliot
    Paris Descartes University, Medicine Faculty UPRES EA 4058 APHP, Hopital Cochin, Service de Rhumatologie B, rue du Faubourg Saint Jacques, Paris, France
    Ann Rheum Dis 69:1683-6. 2010
    ....
  94. ncbi Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy
    Jacques-Eric Gottenberg
    , Paris, France
    Arthritis Rheum 48:2019-24. 2003
    ....
  95. ncbi Influence of patient education on exercise compliance in rheumatoid arthritis: a prospective 12-month randomized controlled trial
    Anne Mayoux-Benhamou
    Department of Rehabilitation, Cochin Hospital, 27 rue du Faubourg Saint Jacques, 75679 Paris Cedex 14, France
    J Rheumatol 35:216-23. 2008
    ..To determine the effect of education on the exercise habits of patients with rheumatoid arthritis (RA) after 6 and 12 months...
  96. ncbi Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment
    Maxime Breban
    Hopital Ambroise Pare, Assistance Publique Hopitaux de Paris, Boulogne Billancourt, France
    Arthritis Rheum 58:88-97. 2008
    ..This study was undertaken to compare the efficacy of continuous treatment with infliximab with that of a treatment regimen adapted to symptom recurrence. Methotrexate (MTX) in combination with infliximab was also tested...
  97. ncbi Minimal clinically important difference, low disease activity state, and patient acceptable symptom state: methodological issues
    Florence Tubach
    , Biostatistique et Recherche Clinique, Groupe Hospitalier Bichat-Claude Bernard (AP-HP, INSERM U738, , Paris, France
    J Rheumatol 32:2025-9. 2005
    ..Threshold values for the MCID and LDAS should be determined according to data-driven and experts' opinions and approaches...
  98. ncbi Do intra-articular therapies work and who will benefit most?
    Laure Gossec
    Service de Rhumatologie B, Hopital Cochin, Rene Descartes University, 27 rue du Faubourg Saint Jacques, 75014 Paris, France
    Best Pract Res Clin Rheumatol 20:131-44. 2006
    ..Some data--mainly from animal studies--suggest a possible long-term chondroprotective effect of hyaluronan. This treatment seems more efficacious in non-radiologically severe osteoarthritis with no or mild effusion...
  99. ncbi B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study
    Jeremie Sellam
    Hopital Bicetre, Assistance Publique Hopitaux de Paris, Le Kremlin Bicetre, France
    Arthritis Rheum 63:933-8. 2011
    ..To examine whether serum B cell markers can predict response to rituximab, a B cell-depleting monoclonal antibody, in patients with refractory rheumatoid arthritis (RA)...
  100. ncbi Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment
    Karine Briot
    Paris Descartes University, Medicine Faculty, Cochin Hospital, Paris, France
    J Rheumatol 35:855-61. 2008
    ..To determine the changes in body weight, body composition, and bone density in patients with spondyloarthropathy (SpA) receiving anti-tumor necrosis factor-alpha (TNF-alpha) treatment...
  101. ncbi B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: A six-month, national, multicenter, open-label study
    Jeremie Sellam
    Hopital Bicetre, Assistance Publique Hopitaux de Paris, INSERM U1012, and Université Paris Sud 11, Le Kremlin Bicetre, France
    Arthritis Rheum 63:933-8. 2011
    ..To examine whether serum B cell markers can predict response to rituximab, a B cell-depleting monoclonal antibody, in patients with refractory rheumatoid arthritis (RA)...